Actively Recruiting
Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2024-10-08
11
Participants Needed
1
Research Sites
22 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.
CONDITIONS
Official Title
Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients treated by gelled alcohol sclerotherapy for aggressive angiomas at the University Hospital of Saint-Etienne
You will not qualify if you...
- Patients not treated by gelled alcohol sclerotherapy
- Age under 18 years
- Presence of any neurological deficit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Saint-Etienne
Saint-Priest-en-Jarez, France, 42270
Actively Recruiting
Research Team
S
Sylvain GRANGE, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here